Brokerages Set KindlyMD, Inc. (NASDAQ:NAKA) Target Price at $19.33

KindlyMD, Inc. (NASDAQ:NAKA) has been assigned a consensus recommendation of “Hold” from the five analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $19.3333.

A number of research firms have issued reports on NAKA. B. Riley Financial lifted their target price on KindlyMD from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday, September 3rd. Wall Street Zen raised KindlyMD to a “sell” rating in a research note on Saturday, May 23rd. TD Cowen increased their price objective on shares of KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of KindlyMD in a report on Friday, August 7th.

Insider Buying and Selling at KindlyMD

In other news, CEO David F. Bailey acquired 4,852 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was bought at an average cost of $6.27 per share, for a total transaction of $30,422.04. Following the acquisition, the chief executive officer directly owned 3,185,246 shares in the company, valued at approximately $19,971,492.42. The trade was a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders purchased 41,904 shares of company stock worth $235,231 in the last 90 days. Insiders own 24.49% of the company’s stock.

Hedge Funds Weigh In On KindlyMD

Several institutional investors have recently bought and sold shares of NAKA. Geode Capital Management LLC boosted its stake in KindlyMD by 76.2% during the second quarter. Geode Capital Management LLC now owns 19,394 shares of the company’s stock worth $484,000 after buying an additional 8,386 shares during the period. Osaic Holdings Inc. acquired a new stake in KindlyMD in the second quarter valued at approximately $215,000. Tower Research Capital LLC TRC boosted its holdings in KindlyMD by 1,638.4% in the third quarter. Tower Research Capital LLC TRC now owns 33,152 shares of the company’s stock worth $827,000 after acquiring an additional 31,245 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in KindlyMD in the 3rd quarter worth approximately $1,007,000. Finally, Vident Advisory LLC purchased a new stake in shares of KindlyMD during the third quarter valued at $2,092,000.

KindlyMD Stock Performance

Shares of KindlyMD stock opened at $8.19 on Monday. The firm has a fifty day moving average of $5.61 and a two-hundred day moving average of $6.85. The stock has a market capitalization of $146.60 million, a price-to-earnings ratio of -0.23 and a beta of 15.99. KindlyMD has a 52 week low of $3.33 and a 52 week high of $143.60.

KindlyMD (NASDAQ:NAKA) last released its earnings results on Thursday, August 13th. The company reported ($6.65) earnings per share for the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. The business had revenue of $35.87 million during the quarter. As a group, research analysts forecast that KindlyMD will post -12.87 EPS for the current fiscal year.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.